Novo Nordisk completes acquisition of Emisphere Technologies

Novo Nordisk has completed the acquisition of Emisphere Technologies, by which it secures the full rights to the technology which has made the diabetes tablet Rybelsus possible, which the firm also plans to use in other treatments.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

On Tuesday, Novo Nordisk completed the acquisition of Emisphere Technologies, according to a statement from the pharmaceutical giant.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading